Reply
Nadim Mahmud, Sumeet K. Asrani – 20 April 2020
Molecular Targets in Cholangiocarcinoma
Colm J. O’Rourke, Patricia Munoz‐Garrido, Jesper B. Andersen – 18 April 2020 – Cholangiocarcinoma (CCA) encompasses a heterogeneous collection of malignancies for which diagnostic biomarkers are lacking and population screening is infeasible because of its status as a rare disease. Coupled with high postsurgical recurrence rates among the minority of patients diagnosed at resectable stages, systemic clinical management will inevitably be required for the majority of patients with CCA with recurrent and advanced disease.
Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID‐19 Pandemic: AASLD Expert Panel Consensus Statement
Oren K. Fix, Bilal Hameed, Robert J. Fontana, Ryan M. Kwok, Brendan M. McGuire, David C. Mulligan, Daniel S. Pratt, Mark W. Russo, Michael L. Schilsky, Elizabeth C. Verna, Rohit Loomba, David E. Cohen, Jorge A. Bezerra, K. Rajender Reddy, Raymond T. Chung – 16 April 2020
Should We Reevaluate Liver Transplantation as an Alternative to Resection for the Treatment of Intrahepatic Cholangiocarcinoma?
Guergana G. Panayotova, James V. Guarrera, Keri E. Lunsford – 16 April 2020
PPARγ Coactivator‐1α Suppresses Metastasis of Hepatocellular Carcinoma by Inhibiting Warburg Effect by PPARγ–Dependent WNT/β‐Catenin/Pyruvate Dehydrogenase Kinase Isozyme 1 Axis
Qiaozhu Zuo, Jia He, Shu Zhang, Hui Wang, Guangzhi Jin, Haojie Jin, Zhuoan Cheng, Xuemei Tao, Chengtao Yu, Botai Li, Chen Yang, Siying Wang, Yuanyuan Lv, Fangyu Zhao, Ming Yao, Wenming Cong, Cun Wang, Wenxin Qin – 16 April 2020
Loss of c‐Jun N‐terminal Kinase 1 and 2 Function in Liver Epithelial Cells Triggers Biliary Hyperproliferation Resembling Cholangiocarcinoma
Francisco Javier Cubero, Mohamed Ramadan Mohamed, Marius M. Woitok, Gang Zhao, Maximilian Hatting, Yulia A. Nevzorova, Chaobo Chen, Johannes Haybaeck, Alain Bruin, Matias A. Avila, Mark V. Boekschoten, Roger J. Davis, Christian Trautwein – 16 April 2020 – Targeted inhibition of the c‐Jun N‐terminal kinases (JNKs) has shown therapeutic potential in intrahepatic cholangiocarcinoma (CCA)‐related tumorigenesis. However, the cell‐type‐specific role and mechanisms triggered by JNK in liver parenchymal cells during CCA remain largely unknown.
Targeting Neoantigens in Hepatocellular Carcinoma for Immunotherapy: A Futile Strategy?
Ligong Lu, Jun Jiang, Meixiao Zhan, Hui Zhang, Qian‐Ting Wang, Sheng‐Nan Sun, Xiao‐Kai Guo, Hua Yin, Yadong Wei, Jun O. Liu, Shi‐You Li, Yong Li, You‐Wen He – 16 April 2020
Targeting Neoantigens in Hepatocellular Carcinoma for Immunotherapy: A Futile Strategy?
Ligong Lu, Jun Jiang, Meixiao Zhan, Hui Zhang, Qian‐Ting Wang, Sheng‐Nan Sun, Xiao‐Kai Guo, Hua Yin, Yadong Wei, Jun O. Liu, Shi‐You Li, Yong Li, You‐Wen He – 16 April 2020
Serum MicroRNA Signatures in Recovery From Acute and Chronic Liver Injury and Selection for Liver Transplantation
Siamak Salehi, Oliver D. Tavabie, Suman Verma, Mark J. W. McPhail, Farzin Farzaneh, William Bernal, Krish Menon, Kosh Agarwal, Varuna R. Aluvihare – 16 April 2020 – We previously demonstrated a distinct hepatic microRNA (miRNA) signature (down‐regulation of miRNA‐23a, ‐150, ‐ 200b, ‐503, and ‐663 and up‐regulation of miRNA‐20a) is associated with successful regeneration in auxiliary liver transplantation (ALT). This study aimed to evaluate whether the serum expression of this regeneration‐linked miRNA signature is associated with clinical outcomes in acute and chronic liver disease.